Postal addressDepartment of Cancer Research and Molecular Medicine Norwegian University of Science and Technology Postboks 8905 7491 Trondheim Norway
Background and activities
Multiple myeloma is a cancer caused by accumulation of malignant plasma cells within the bone marrow. Almost all myeloma patients suffer from an osteolytic bone disease, caused by increased numbers of cells degrading bone (osteoclasts) and reduced numbers of cells producing bone (osteoblasts). Bone destruction is also common in inflammtory diseases such as rheumatoid arthritis.
My research focus is on how myeloma cells, myeloma derived factors and inflammation affects the activity and differentiation of osteoblast and osteoclasts. .
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
- (2014) The Primary Function of gp130 Signaling in Osteoblasts is to Maintain bone Formation and Strength, Rather than Promote Osteoclast Formation. Journal of Bone and Mineral Research. volum 29 (6).
- (2014) Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer Journal. volum 4.
- (2013) Dickkopf-1 is associated with periarticular bone loss in patients with rheumatoid arthritis. Open Journal of Rheumatology and Autoimmune Diseases.
- (2013) Anti-c-MET Nanobody® – a new potential drug in multiple myeloma treatment. European Journal of Haematology. volum 91 (5).
- (2012) Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. volum 26.
- (2012) Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. Journal of Bone and Mineral Metabolism. volum 30 (1).
- (2012) Properties and cell compatibility of mineralized alginate hydrogel beads. European Cells and Materials. volum 23.
- (2012) Investigation of mineralized alginate gels as a scaffold material for stem cell based bone tissue engineering. Journal of Tissue Engineering and Regenerative Medicine. volum 6.
- (2011) Association Between High Plasma Levels of Hepatocyte Growth Factor and Progression of Radiographic Damage in the Joints of Patients With Rheumatoid Arthritis. Arthritis and Rheumatism. volum 63 (3).
- (2011) BONE MORPHOGENETIC PROTEINS INDUCE APOPTOSIS BY SMAD-DEPENDENT DOWNREGULATION OF MYC. Haematologica. volum 96.
- (2011) CpG-ODN inhibits Smad-dependent BMP signaling; Effects on myeloma cell apoptosis and in vitro osteoblastogenesis. Bone. volum 48 (1).
- (2010) DKK1, AN INHIBITOR OF BONE FORMATION IS AN INDEPENDENT PREDICTOR OF HAND BONE LOSS IN RHEUMATOID ARTHRITIS. Scandinavian Journal of Rheumatology. volum 39.
- (2010) CpG-Oligodeoxynucleotide Inhibits Smad-Dependent Bone Morphogenetic Protein Signaling: Effects on Myeloma Cell Apoptosis and In Vitro Osteoblastogenesis. Journal of Immunology. volum 185 (6).
- (2009) Does Toll-like Receptor 9 Signaling Play a Role in Myeloma Disease Progression?. Clinical Lymphoma & Myeloma. volum 9.
- (2008) Hepatocyte growth factor (HGF) in the pathogenesis of multiple myeloma. Cellular Therapy and Transplantation. volum 1 (1).
- (2008) High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. European Journal of Haematology. volum 80.
- (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. volum 109 (7).
- (2006) Bone disease in multiple myeloma. Medical Oncology. volum 23 (4).
- (2006) HGF inhibits BMP-2 induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. volum 108.
- (2006) HGF Inhibits BMP-Induced Osteoblastogenesis: Implications for the Bone Disease in Multiple Myeloma. Blood. volum 108.